NCT04485559 2026-03-16
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
University of California, San Francisco
Phase 1 Recruiting
Clinical Trials
40 trialsNCT05843253 2026-03-04
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
NCT04895748 2026-03-03
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Phase 1 Terminated
NCT06955169 2026-02-17
MOMENTUM-1
RTOG Foundation, Inc.
Phase 2 Recruiting
NCT05476939 2026-02-05
BIOMEDE 2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT06326190 2025-09-16
LUMEN-1
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Recruiting
NCT03834740 2025-05-30
A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Completed
NCT05432518 2025-04-25
Pilot Trial for Treatment of Recurrent Glioblastoma
AHS Cancer Control Alberta
Phase EARLY_PHASE1 Recruiting
NCT06126588 2025-03-11
ELUMEN
Central Hospital, Nancy, France
Phase 2 Recruiting
NCT01345136 2024-02-13
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT02332902 2023-12-20
DCLNF1
The University of Texas Health Science Center, Houston
Phase 2 Completed
NCT03245151 2023-08-30
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Eisai Inc.
Phase 1/2 Completed
NCT00387400 2023-08-04
Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme
Canadian Cancer Trials Group
Phase 1 Completed
NCT02333565 2023-05-25
CEVOREM
Assistance Publique Hopitaux De Marseille
Phase 2 Completed
NCT03355794 2023-01-13
A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
Children's Hospital Medical Center, Cincinnati
Phase 1 Completed
NCT02023905 2022-12-29
Everolimus With and Without Temozolomide in Adult Low Grade Glioma
University of California, San Francisco
Phase 2 Terminated
NCT01062399 2022-06-09
RTOG 0913
Radiation Therapy Oncology Group
Phase 1/2 Completed
NCT01434602 2022-06-01
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00972335 2021-11-10
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT03387020 2021-08-27
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
Pediatric Brain Tumor Consortium
Phase 1 Completed
NCT00823459 2020-07-28
Everolimus in Treating Patients With Recurrent Low-Grade Glioma
University of California, San Francisco
Phase 2 Completed
NCT01880749 2020-05-13
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
NYU Langone Health
Phase EARLY_PHASE1 Completed
NCT00553150 2020-02-13
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT01158651 2020-02-05
NFC-RAD001
University of Alabama at Birmingham
Phase 2 Completed
NCT01305941 2018-12-17
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00782626 2018-08-15
Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02233049 2018-07-23
BIOMEDE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Unknown
NCT01508104 2017-08-23
Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors
University of Cincinnati
Phase 1 Terminated
NCT01419639 2017-07-18
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
NYU Langone Health
Phase 2 Completed
NCT01490476 2017-05-23
AFINF2
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT01204476 2016-07-15
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01365468 2016-05-12
Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)
Novartis
Phase 2 Terminated
NCT00789828 2016-02-03
EXIST-1
Novartis
Phase 3 Completed
NCT00085566 2016-01-20
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00756340 2015-10-14
A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT01152827 2015-05-20
PheoCarcRAD001
Seoul National University Hospital
Phase 2 Completed
NCT00187174 2015-03-04
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00107237 2013-06-12
AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme
Novartis
Phase 1/2 Completed
NCT00613132 2013-02-20
Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
Duke University
Phase 1 Completed
NCT00892801 2012-03-12
Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Terminated